The Identification and Analysis of MicroRNAs Combined Biomarkers for Hepatocellular Carcinoma Diagnosis | Bentham Science
Login Register Cart 0
Generic placeholder image

Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1573-4064
ISSN (Online): 1875-6638

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Identification and Analysis of MicroRNAs Combined Biomarkers for Hepatocellular Carcinoma Diagnosis

Author(s): Yi Shi, Jingrui Men, Hongliang Sun and Jianjun Tan*

Volume 18, Issue 10, 2022

Published on: 23 May, 2022

Page: [1073 - 1085] Pages: 13

DOI: 10.2174/1573406418666220404084532

Price: $65

Open Access Journals Promotions 2
Abstract

Background: Hepatocellular carcinoma (HCC) is a common malignant tumor with high morbidity and mortality globally. Compared with traditional diagnostic methods, microRNAs (miRNAs) are novel biomarkers with higher accuracy.

Objective: We aimed to identify combinatorial biomarkers of miRNAs to construct a classification model for the diagnosis of HCC.

Methods: The mature miRNA expression profile data of six cancers (liver, lung, gastric, breast, prostate, and colon) were retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database with accession number GSE36915, GSE29250, GSE99417, GSE41970, GSE64333 and GSE35982. The messenger RNA (mRNA) expression profile data of these six cancers were obtained from TCGA. Three R software packages, student’s t-test, and a normalized foldchange method were utilized to identify HCC-specific differentially expressed miRNAs (DEMs). Using all combinations of obtained HCC-specific DEMs as input features, we constructed a classification model by support vector machine searching for the optimal combination. Furthermore, target genes prediction was conducted on the miRWalk 2.0 website to obtain differentially expressed mRNAs (DEmRNAs), and KEGG pathway enrichment was analyzed on the DAVID website.

Results: The optimal combination consisted of four miRNAs (hsa-miR-130a-3p, hsa-miR-450b-5p, hsa-miR-136-5p, and hsa-miR-24-1-5p), of which the last one has not been currently reported to be relevant to HCC. The target genes of hsa-miR-24-1-5p (CDC7, ACACA, CTNNA1, and NF2) were involved in the cell cycle, AMPK signaling pathway, Hippo signaling pathway, and insulin signaling pathway, which affect the proliferation, metastasis, and apoptosis of cancer cells. Moreover, the area under the receiver operating characteristic curves of the four miRNAs were all higher than 0.85.

Conclusion: These results suggest that the miRNAs combined biomarkers were reliable for the diagnosis of HCC. Hsa-miR-24-1-5p was a novel biomarker for HCC diagnosis identified in this study.

Keywords: Hepatocellular carcinoma, microRNAs, biomarker, diagnosis, TCGA, GEO.

« Previous Next »
Graphical Abstract

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of inci-dence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Chapman, W.C.; Korenblat, K.M.; Fowler, K.J.; Saad, N.; Khan, A.S.; Subramanian, V.; Doyle, M.B.M.; Dageforde, L.A.; Tan, B.; Grier-son, P.; Lin, Y.; Xu, M.; Brunt, E.M. Hepatocellular carcinoma: Where are we in 2018? Curr. Probl. Surg., 2018, 55(11), 450-503.
[http://dx.doi.org/10.1067/j.cpsurg.2018.10.002] [PMID: 30526875]
[3]
Duan, J.; Wu, Y.; Liu, J.; Zhang, J.; Fu, Z.; Feng, T.; Liu, M.; Han, J.; Li, Z.; Chen, S. Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine. J. Hepatocell. Carcinoma, 2019, 6, 151-166.
[http://dx.doi.org/10.2147/JHC.S224849] [PMID: 31696097]
[4]
Choi, J.Y. Lee, J.M.; Sirlin, C.B.C.T. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology, 2014, 273(1), 30-50.
[http://dx.doi.org/10.1148/radiol.14132362] [PMID: 25247563]
[5]
Reichl, P.; Mikulits, W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). Oncol. Rep., 2016, 36(2), 613-625.
[http://dx.doi.org/10.3892/or.2016.4842] [PMID: 27278244]
[6]
Tsuchiya, N.; Sawada, Y.; Endo, I.; Saito, K.; Uemura, Y.; Nakatsura, T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J. Gastroenterol., 2015, 21(37), 10573-10583.
[http://dx.doi.org/10.3748/wjg.v21.i37.10573] [PMID: 26457017]
[7]
Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A.; Lin, D.W.; Urban, N.; Drescher, C.W.; Knudsen, B.S.; Stirewalt, D.L.; Gentleman, R.; Vessella, R.L.; Nelson, P.S.; Martin, D.B.; Tewari, M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA, 2008, 105(30), 10513-10518.
[http://dx.doi.org/10.1073/pnas.0804549105] [PMID: 18663219]
[8]
Jia, X.; Liu, J.; Gao, Y.; Huang, Y.; Du, Z. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: A systematic review with meta-analysis. Arch. Med. Res., 2014, 45(7), 580-588.
[http://dx.doi.org/10.1016/j.arcmed.2014.11.002] [PMID: 25446613]
[9]
Li, J.; Wang, T.; Jin, B.; Li, W.; Wang, Z.; Zhang, H.; Song, Y.; Li, N. Diagnosis accuracy of serum glypican-3 level in patients with hepa-tocellular carcinoma: A systematic review with meta-analysis. Int. J. Biol. Markers, 2018, 33(4), 353-363.
[http://dx.doi.org/10.1177/1724600818784409] [PMID: 30071741]
[10]
Schraml, C.; Kaufmann, S.; Rempp, H.; Syha, R.; Ketelsen, D.; Notohamiprodjo, M.; Nikolaou, K. Imaging of HCC-current state of the art. Diagnostics (Basel), 2015, 5(4), 513-545.
[http://dx.doi.org/10.3390/diagnostics5040513] [PMID: 26854169]
[11]
Wen, Y.; Han, J.; Chen, J.; Dong, J.; Xia, Y.; Liu, J.; Jiang, Y.; Dai, J.; Lu, J.; Jin, G.; Han, J.; Wei, Q.; Shen, H.; Sun, B.; Hu, Z. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int. J. Cancer, 2015, 137(7), 1679-1690.
[http://dx.doi.org/10.1002/ijc.29544] [PMID: 25845839]
[12]
Okajima, W.; Komatsu, S.; Ichikawa, D.; Miyamae, M.; Kawaguchi, T.; Hirajima, S.; Ohashi, T.; Imamura, T.; Kiuchi, J.; Arita, T.; Kon-ishi, H.; Shiozaki, A.; Moriumura, R.; Ikoma, H.; Okamoto, K.; Taniguchi, H.; Itoh, Y.; Otsuji, E. Circulating microRNA profiles in plas-ma: Identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Oncotarget, 2016, 7(33), 53820-53836.
[http://dx.doi.org/10.18632/oncotarget.10781] [PMID: 27462777]
[13]
Amr, K.S.; Ezzat, W.M.; Elhosary, Y.A.; Hegazy, A.E.; Fahim, H.H.; Kamel, R.R. The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma. Gene, 2016, 575(1), 66-70.
[http://dx.doi.org/10.1016/j.gene.2015.08.038] [PMID: 26302751]
[14]
Shi, B.M.; Lu, W.; Ji, K.; Wang, Y.F.; Xiao, S.; Wang, X.Y. Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma. World J. Gastroenterol., 2017, 23(20), 3713-3720.
[http://dx.doi.org/10.3748/wjg.v23.i20.3713] [PMID: 28611524]
[15]
Wang, X.; Zhang, J.; Zhou, L.; Lu, P.; Zheng, Z.G.; Sun, W.; Wang, J.L.; Yang, X.S.; Li, X.L.; Xia, N.; Zhang, N.; Dou, K.F. Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): Clinical analyses of patients and an HCC rat model. Int. J. Clin. Exp. Pathol., 2015, 8(2), 1466-1478.
[PMID: 25973032]
[16]
Gedaly, R.; Angulo, P.; Hundley, J.; Daily, M.F.; Chen, C.; Evers, B.M. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J. Surg. Res., 2012, 176(2), 542-548.
[http://dx.doi.org/10.1016/j.jss.2011.10.045] [PMID: 22261591]
[17]
Huang, F.Y.; Wong, D.K.H.; Tsui, V.W.M.; Seto, W.K.; Mak, L.Y.; Cheung, T.T. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. BMC Cancer, 2019, 19(1), 789.
[18]
Kim, J.U.; Shariff, M.I.F.; Crossey, M.M.E.; Gomez-Romero, M.; Holmes, E.; Cox, I.J.; Fye, H.K.; Njie, R.; Taylor-Robinson, S.D. Hepa-tocellular carcinoma: Review of disease and tumor biomarkers. World J. Hepatol., 2016, 8(10), 471-484.
[http://dx.doi.org/10.4254/wjh.v8.i10.471] [PMID: 27057305]
[19]
Vilchez, V.; Turcios, L.; Marti, F.; Gedaly, R. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J. Gastroenterol., 2016, 22(2), 823-832.
[http://dx.doi.org/10.3748/wjg.v22.i2.823] [PMID: 26811628]
[20]
Chen, X.; Zhang, Q.; Ma, W.J.; Lan, T.; Hong, Z.F.; Yuan, Y.F. The abnormal expression of microRNA-542-3p in hepatocellular carcino-ma and its clinical significance. Dis. Markers, 2018, 2018
[http://dx.doi.org/10.1155/2018/3973250]
[21]
Li, X.; Yang, W.; Lou, L.; Chen, Y.; Wu, S.; Ding, G. microRNA: A promising diagnostic biomarker and therapeutic target for hepatocellu-lar carcinoma. Dig. Dis. Sci., 2014, 59(6), 1099-1107.
[http://dx.doi.org/10.1007/s10620-013-3006-1] [PMID: 24390674]
[22]
Mathew, S.; Ali, A.; Abdel-Hafiz, H.; Fatima, K.; Suhail, M.; Archunan, G.; Begum, N.; Jahangir, S.; Ilyas, M.; Chaudhary, A.G.; Al Qahtani, M.; Mohamad Bazarah, S.; Qadri, I. Biomarkers for virus-induced Hepatocellular Carcinoma (HCC). Infect. Genet. Evol., 2014, 26, 327-339.
[http://dx.doi.org/10.1016/j.meegid.2014.06.014] [PMID: 24956436]
[23]
Shao, P.; Sun, D.; Wang, L.; Fan, R.; Gao, Z. Deep sequencing and comprehensive expression analysis identifies several molecules poten-tially related to human poorly differentiated hepatocellular carcinoma. FEBS Open Bio, 2017, 7(11), 1696-1706.
[http://dx.doi.org/10.1002/2211-5463.12310] [PMID: 29123978]
[24]
Adams, B.D.; Kasinski, A.L.; Slack, F.J. Aberrant regulation and function of microRNAs in cancer. Curr. Biol., 2014, 24(16), R762-R776.
[http://dx.doi.org/10.1016/j.cub.2014.06.043] [PMID: 25137592]
[25]
Tomczak, K. Czerwińska, P.; Wiznerowicz, M. The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge. Contemp. Oncol. (Pozn.), 2015, 19(1A), A68-A77.
[http://dx.doi.org/10.5114/wo.2014.47136] [PMID: 25691825]
[26]
Neveol, A.; Wilbur, W.J.; Lu, Z.Y. Improving links between literature and biological data with text mining: A case study with GEO, PDB and MEDLINE. Database (Oxford), 2012, 2012, bas026.
[27]
Zhang, Z.H. Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann. Transl. Med., 2016, 4(2), 30.
[28]
Du, W.; Cao, Z.B.; Wang, Y.; Zhou, F.F.; Pang, W.; Chen, X.; Tian, Y.; Liang, Y. Specific biomarkers: Detection of cancer biomarkers through high-throughput transcriptomics data. Cognit. Comput., 2015, 7(6), 652-666.
[http://dx.doi.org/10.1007/s12559-015-9336-x]
[29]
Dickinson, R.J.; Delavaine, L.; Cejudo-Marín, R.; Stewart, G.; Staples, C.J.; Didmon, M.P.; Trinidad, A.G.; Alonso, A.; Pulido, R.; Keyse, S.M. Phosphorylation of the kinase interaction motif in Mitogen-Activated Protein (MAP) kinase phosphatase-4 mediates cross-talk be-tween protein kinase A and MAP kinase signaling pathways. J. Biol. Chem., 2011, 286(44), 38018-38026.
[http://dx.doi.org/10.1074/jbc.M111.255844] [PMID: 21908610]
[30]
Kim, E.K.; Choi, E.J. Compromised MAPK signaling in human diseases: An update. Arch. Toxicol., 2015, 89(6), 867-882.
[http://dx.doi.org/10.1007/s00204-015-1472-2] [PMID: 25690731]
[31]
Seternes, O.M.; Kidger, A.M.; Keyse, S.M. Dual-specificity MAP kinase phosphatases in health and disease. Biochim. Biophys. Acta Mol. Cell Res., 2019, 1866(1), 124-143.
[http://dx.doi.org/10.1016/j.bbamcr.2018.09.002] [PMID: 30401534]
[32]
Knockleby, J.; Kim, B.J.; Mehta, A.; Lee, H. Cdk1-mediated phosphorylation of Cdc7 suppresses DNA re-replication. Cell Cycle, 2016, 15(11), 1494-1505.
[http://dx.doi.org/10.1080/15384101.2016.1176658] [PMID: 27105124]
[33]
Hong, D.S.; Banerji, U.; Tavana, B.; George, G.C.; Aaron, J.; Kurzrock, R. Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. Cancer Treat. Rev., 2013, 39(4), 375-387.
[http://dx.doi.org/10.1016/j.ctrv.2012.10.001] [PMID: 23199899]
[34]
Zhou, Y.; Deng, X.; Zang, N.; Li, H.; Li, G.; Li, C.; He, M. Transcriptomic and proteomic investigation of HSP90A as a potential bi-omarker for HCC. Med. Sci. Monit., 2015, 21, 4039-4049.
[http://dx.doi.org/10.12659/MSM.896712] [PMID: 26704341]
[35]
Qin, L.; Huang, H.; Huang, J.; Wang, G.; Huang, J.; Wu, X.; Li, J.; Yi, W.; Liu, L.; Huang, D. Biological characteristics of heat shock pro-tein 90 in human liver cancer cells. Am. J. Transl. Res., 2019, 11(4), 2477-2483.
[PMID: 31105855]
[36]
Wang, N.; Chen, S.P.; Zhang, B.; Li, S.F.; Jin, F.; Gao, D. 8u, a pro-apoptosis/cell cycle arrest compound, suppresses invasion and metas-tasis through HSP90 alpha downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells. Sci. Rep., 2018, 8(1), 309.
[37]
Vara-Ciruelos, D.; Russell, F.M.; Hardie, D.G. The strange case of AMPK and cancer: Dr Jekyll or Mr Hyde? Open Biol., 2019, 9(7), 190099.

Rights & Permissions Print Cite
Article Metrics
47
1
1
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy